Dr. Reddy's secures Brazil approval for semaglutide

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628 Dr. Reddy's Laboratories Limited (

) has received marketing authorisation from Brazil's health regulator, ANVISA, for its generic semaglutide injection. The approval allows the company to expand its presence in the Latin American market. What happened? The product is indicated for adults with insufficiently controlled Type 2 diabetes and will be available as a pre-filled, multi-dose injectable pen in two presentations: 2 mg/1.5 mL and 4 mg/3 mL. It is designed for once-weekly administration. Dr. Reddy's plans to launch the product in Brazil in partnership with Aché. Brazil represents a significant potential market, with approximately 16.6 million adults aged 20–79 living with diabetes. The company's statement estimates the country's semaglutide market for diabetes at around $244.6 million. Why does it matter? The approval expands Dr. Reddy's semaglutide presence beyond India and strengthens its entry into a key Latin American market. It also marks regulatory progress after ANVISA rejected its earlier application in April 2026 over technical requirements. My view This approval is an important step in the company's global generics strategy. Semaglutide offers a potential growth opportunity, but commercial success will depend on launch execution, pricing, competition and the ability to maintain product quality and supply. What I am watching next I would track the Brazilian launch timeline, market penetration, pricing strategy, partnership execution and further regulatory approvals across international markets. No Recommendations Source: Business Standard Disclosure: I, my entity, associates or relatives do not have any holding, position or other material interest in Dr. Reddy's Laboratories Limited.